Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Sham-controlled Double-masked Phase 2a Study of the Efficacy, Safety and Tolerability of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema Who Have Had Prior Anti-vascular Endothelial Growth Factor Treatment

NCT03466099 is registered in ClinicalTrials.gov with KalVista Pharmaceuticals, Ltd. as lead sponsor.

NCT NCT03466099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03466099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Sham-controlled Double-masked Phase 2a Study of the Efficacy, Safety and Tolerability of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema Who Have Had Prior Anti-vascular Endothelial Growth Factor Treatment
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Phase
Phase 2
Overall status
Completed
Start date
February 16, 2018
Completion date
October 10, 2019
Enrollment
129 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema